---
title: Serotonin Transporter Density in Late-life Depression With and Without Dementia
nct_id: NCT01548937
overall_status: COMPLETED
phase: PHASE2
sponsor: Chang Gung Memorial Hospital
study_type: INTERVENTIONAL
primary_condition: Melancholia
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT01548937.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT01548937"
ct_last_update_post_date: 2016-01-28
last_seen_at: "2026-05-12T06:25:47.114Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Serotonin Transporter Density in Late-life Depression With and Without Dementia

**NCT ID:** [NCT01548937](https://clinicaltrials.gov/study/NCT01548937)

## Key Facts

- **Status:** COMPLETED
- **Phase:** PHASE2
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 39
- **Lead Sponsor:** Chang Gung Memorial Hospital
- **Conditions:** Melancholia
- **Start Date:** 2010-05
- **Completion Date:** 2012-12
- **CT.gov Last Update:** 2016-01-28

## Brief Summary

This study will recruit a total of 40 evaluable subjects (20 cognitively depressive, and 20 AD depressive); each evaluable subject involved in this study must fulfill all the inclusion and exclusion criteria according the subject grouping.

Safety measurement will be evaluated by medical history, vital signs, physical examinations, laboratory examinations and collecting of adverse events.

This study is expected to be completed in a period of 3 years.

## Detailed Description

Depression and dementia are the two common psychiatric disorders in the elder subjects. Alzheimer's disease (AD) is the most frequent cause of dementia and about 20% of them have depression. Depression subjects are associated with more rapid cognitive decline, a poorer response to treatment. Post mortem study showed close relationship between AD and disruptions of the serotonergic system, including loss of serotnergic neurons at brain stem. However, the alternations in presynaptic serotonin function relative to demented or non-demented subjects remain to be investigated in living subjects. In this study, the investigators will collect 40 elder subjects (i.e., age above or equal to 50 years old). The serotonin transporter activity will be compared between subjects with or without dementia using I-123 ADAM images. The single photon emission tomography (SPECT) will be compared to recent (within 6 months) F-18 FDG PET images for further investigation.

## Eligibility

- **Minimum age:** 50 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

1. Patients may be enrolled in the AD depressive group if they:

   * Are males or females at least 50 years of age;
   * Fulfilled the DSM-IV criteria for Major depressive disorder (APA, 1994) by MINI interview.
   * Meet the NINCDS/ADRDA(National institute of Neurological and Communicative Disorders and Stroke/Alzheimer's Disease and Related Disorders Association) criteria for probable AD
   * A Mini Mental State Examination (MMSE) score at screening between 10 and 24 inclusive;
   * Give informed consent. If the patient is incapable of giving informed consent, the caregiver may consent on behalf of the patient (the patient must still confirm assent).
2. Patients may be enrolled in the cognitively depressive group if they:

   * Are males or females at least 50 years of age;
   * Fulfilled the DSM-IV criteria for Major depressive disorder (APA, 1994) by MINI interview.
   * Memory function above the lower normal limits (i.e. 1.5 SD above the mean) on tests for episodic memory.
   * Clinical Dementia Rating = 0. Memory Box score must be 0.
   * Cognitively normal, based on an absence of significant impairment in cognitive functions or ADL.
   * A MMSE score at screening \> 24 for those with education level of 6 years or above and \> 17 for those are illiterate;
   * Give informed consent.

Exclusion Criteria:

* Pregnant or becoming pregnant during the study (as documented by pregnancy testing at screening or at any date during the study according to the PI discretion) or current breast feeding.
* Conditions affecting brain structure or function (e.g., stroke, diabetes, head trauma, depression) or use of cognitively
* Substance abuse.
* Alcohol dependence
```

## Arms

- **I-123 ADAM** (EXPERIMENTAL) — I-123 ADAM Serotonin transporter imaging

## Interventions

- **I-123 ADAM** (DRUG) — This study will recruit a total of 40 evaluable subjects (20 cognitively depressive, and 20 AD depressive), Each evaluable subject involved in this study must fulfill all the inclusion and exclusion criteria according the subject grouping.

Safety measurement will be evaluated by medical history, vital signs, physical examinations, laboratory examinations and collecting of adverse events.

## Primary Outcomes

- **Evaluate the differences of serotonin transporter activity among depressive patient with or without dementia.** _(time frame: three years)_ — To expand the database of I-123 ADAM SPECT imaging in AD depressive and cognitively depressive patients to refine the definition of a positive scan in patient with AD and MDD.

## Secondary Outcomes

- **Evaluate the relationship between the serotonin transporter activity and F-18 FDG PET image patter.** _(time frame: three years)_

## Recent Field Changes (last 30 days)

- `outcomes.primary` — added _(2026-05-12)_
- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT01548937.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT01548937*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*